BAX on XNYS, Health Care, Baxter International Inc., job postings
Measures activity, not value. Not investment advice.
Shares up 46% in a year, but Baxter still lost $723M over 12 months on revenue up 5.3%.
GoodInstitutional holders up 8.3%, to 728 from 672 last quarter
Written by AI from the data on this page, 21 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Industry
Surgical & medical instruments & apparatus (Health Care)
expected around 11 Feb 2027 (an estimate: a year ago it reported on 12 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $3.1B, net income $294.0M.
31 Dec 2021RevenueNet incomeNet losstallest bar $3.9B30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$3.1B
$294.0M
30 Jun 2026
$3.0B
$126.0M
31 Mar 2026
$2.8B
-$15.0M
31 Dec 2025
–
-$1.1B
30 Sep 2025
$2.9B
-$46.0M
30 Jun 2025
$2.9B
$91.0M
31 Mar 2025
$2.7B
$126.0M
31 Dec 2024
$2.8B
-$512.0M
30 Sep 2024
$2.8B
$140.0M
30 Jun 2024
$3.9B
-$314.0M
31 Mar 2024
$3.7B
$37.0M
31 Dec 2023
$3.9B
$245.0M
30 Sep 2023
$3.8B
$2.5B
30 Jun 2023
$3.8B
-$141.0M
31 Mar 2023
$3.8B
$44.0M
31 Dec 2022
$3.7B
$181.0M
30 Sep 2022
$3.9B
-$2.9B
30 Jun 2022
$3.9B
$252.0M
31 Mar 2022
$3.8B
$71.0M
31 Dec 2021
$3.6B
$238.0M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$12.0B
$11.3B
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+6.0%
+13%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$723.0M
-$341.0M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$1.42
-$0.66
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
29.2%
33.3%
60.5%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-1.8%
-0.1%
-8.3%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-6.0%
-3.0%
-10.1%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-10.5%
-26.3%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$2.0B
$1.7B
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$844.0M
$755.0M
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$1.1B (net cash)
-$971.0M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.13
0.31
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$12.57
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
28.0
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
1.1
2.3
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
1.0
2.5
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
2.0
2.8
Dividend yieldiDividends per share declared in the latest fiscal year divided by the share price.
2.0%
1.4%
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+4.9%
$3.1B vs $2.9B (quarter ended 30 Sep 2026)
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+8.3%
728 13F filers vs 672
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
over 100%
519.9M shares held by 13F filers (30 Sep 2026) of 517.3M outstanding (22 Oct 2026); above 100%: the share count is probably stale
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
4.6%
23.7M shares sold short (30 Oct 2026) of 517.3M outstanding (22 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
3.0
23.7M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-0.4%
23.8M shares sold short in the report before, 23.7M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
48%
48% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 61%
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
$1.5M
the 12 months before: $0
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$1.3M
4 quarters
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
23
23 articles in the last 7 days; its usual week has 4 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
5.8×
23 articles in the last 7 days; its usual week has 4.
Price $25.39 on 20 Nov 2026, +46% over 12 months (12-month range $15.80 to $28.35)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: $0).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 8 published in the last 12 months (none in the 12 months before).Revenue per quarter. Revenue $3.1B in the latest quarter, +4.9% on a year earlier.Capital spending per quarter. Capital spending $172.0M in the latest quarter, +23% on a year earlier.Institutional holders (13F filers). 728 13F filers reported holding it in the latest 13F quarter, +6.9% on a year earlier.Federal obligations. Federal obligations: $15.9M published in the last 12 months, +141% on the 12 months before.Lobbying spend. Lobbying spend: $1.3M published in the last 12 months, -27% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.
Quarter ended 31 Dec 2021: $3.6B, +12% on a year earlier; public on 24 Feb 2022
Quarter ended 31 Mar 2022: $3.8B, +28% on a year earlier; public on 29 Apr 2022
Quarter ended 30 Jun 2022: $3.9B, +23% on a year earlier; public on 29 Jul 2022
Quarter ended 30 Sep 2022: $3.9B, +21% on a year earlier; public on 28 Oct 2022
Quarter ended 31 Dec 2022: $3.7B, +5.2% on a year earlier; public on 9 Feb 2024
Quarter ended 31 Mar 2023: $3.8B, -1.5% on a year earlier; public on 28 Apr 2023
Quarter ended 30 Jun 2023: $3.8B, -0.5% on a year earlier; public on 28 Jul 2023
Quarter ended 30 Sep 2023: $3.8B, -2.2% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $3.9B, +3.7% on a year earlier; public on 9 Feb 2024
Quarter ended 31 Mar 2024: $3.7B, -1.0% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $3.9B, +2.0% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $2.8B, -27% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $2.8B, -29% on a year earlier; public on 22 Feb 2025
Quarter ended 31 Mar 2025: $2.7B, -27% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $2.9B, -26% on a year earlier; public on 6 Aug 2025
Quarter ended 30 Sep 2025: $2.9B, +4.3% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Mar 2026: $2.8B, +2.8% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $3.0B, +5.1% on a year earlier; public on 31 Jul 2026
Quarter ended 30 Sep 2026: $3.1B, +4.9% on a year earlier; public on 30 Oct 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $235.0M; public on 24 Feb 2022
Quarter ended 31 Mar 2022: $140.0M, -18% on a year earlier; public on 29 Apr 2022
Quarter ended 30 Jun 2022: $171.0M, +8.2% on a year earlier; public on 29 Jul 2022
Quarter ended 30 Sep 2022: $168.0M, -6.1% on a year earlier; public on 28 Oct 2022
Quarter ended 31 Dec 2022: $200.0M, -15% on a year earlier; public on 10 Feb 2023
Quarter ended 31 Mar 2023: $172.0M, +23% on a year earlier; public on 28 Apr 2023
Institutional holders (13F filers)
31 Dec 2021 report: 1,022; public on 14 Feb 2022
31 Mar 2022 report: 1,066; public on 16 May 2022
30 Jun 2022 report: 1,000; public on 15 Aug 2022
30 Sep 2022 report: 913; public on 14 Nov 2022
31 Dec 2022 report: 918; public on 14 Feb 2023
31 Mar 2023 report: 880; public on 15 May 2023
30 Jun 2023 report: 893; public on 14 Aug 2023
30 Sep 2023 report: 822; public on 14 Nov 2023
31 Dec 2023 report: 841; public on 14 Feb 2024
31 Mar 2024 report: 876; public on 15 May 2024
30 Jun 2024 report: 826; public on 14 Aug 2024
30 Sep 2024 report: 837; public on 14 Nov 2024
31 Dec 2024 report: 773; public on 14 Feb 2025
31 Mar 2025 report: 791; public on 15 May 2025
30 Jun 2025 report: 735; public on 14 Aug 2025
30 Sep 2025 report: 681; public on 14 Nov 2025
31 Dec 2025 report: 676; public on 17 Feb 2026
31 Mar 2026 report: 640; public on 15 May 2026
30 Jun 2026 report: 672; public on 14 Aug 2026
30 Sep 2026 report: 728; public on 16 Nov 2026
Federal obligations
Month from 1 Dec 2021: $35K published
Month from 1 Jan 2022: $69K published
Month from 1 Feb 2022: $201 published
Month from 1 Mar 2022: $102K published
Month from 1 Apr 2022: $51K published
Month from 1 May 2022: $2.1M published
Month from 1 Jun 2022: $2.0M published
Month from 1 Jul 2022: $2.2M published
Month from 1 Aug 2022: $3.3M published
Month from 1 Sep 2022: $14.6M published
Month from 1 Oct 2022: $3.1M published
Month from 1 Nov 2022: $1.0M published
Month from 1 Dec 2022: $670K published
Month from 1 Jan 2023: $413K published
Month from 1 Feb 2023: $7.5M published
Month from 1 Mar 2023: $9.3M published
Month from 1 Apr 2023: $346K published
Month from 1 May 2023: $122K published
Month from 1 Jun 2023: $851K published
Month from 1 Jul 2023: $41K published
Month from 1 Aug 2023: $49K published
Month from 1 Sep 2023: $3.5M published
Month from 1 Oct 2023: $1.8M published
Month from 1 Nov 2023: $195K published
Month from 1 Dec 2023: $53K published
Month from 1 Jan 2024: $314K published
Month from 1 Feb 2024: $287K published
Month from 1 Mar 2024: $118K published
Month from 1 Apr 2024: $514K published
Month from 1 May 2024: -$163K published
Month from 1 Jun 2024: $9.0M published
Month from 1 Jul 2024: $342K published
Month from 1 Aug 2024: $41K published
Month from 1 Sep 2024: $919K published
Month from 1 Oct 2024: $1.1M published
Month from 1 Nov 2024: $62K published
Month from 1 Dec 2024: $621K published
Month from 1 Jan 2025: $61K published
Month from 1 Feb 2025: $231K published
Month from 1 Mar 2025: $212K published
Month from 1 Apr 2025: $3K published
Month from 1 May 2025: -$39K published
Month from 1 Jun 2025: $13K published
Month from 1 Jul 2025: -$42K published
Month from 1 Aug 2025: $222K published
Month from 1 Sep 2025: $25K published
Month from 1 Oct 2025: $785K published
Month from 1 Nov 2025: $4.5M published
Month from 1 Dec 2025: $106K published
Month from 1 Jan 2026: $222K published
Month from 1 Feb 2026: $115K published
Month from 1 Mar 2026: $184K published
Month from 1 Apr 2026: $48K published
Month from 1 May 2026: $110K published
Month from 1 Jun 2026: $570K published
Month from 1 Jul 2026: $125K published
Month from 1 Aug 2026: $14.4M published
Month from 1 Sep 2026: $24K published
Month from 1 Oct 2026: $46K published
Month from 1 Nov 2026: -$5K published
Lobbying spend
Quarter from 1 Jan 2022: $570K published
Quarter from 1 Apr 2022: $670K published
Quarter from 1 Jul 2022: $630K published
Quarter from 1 Oct 2022: $670K published
Quarter from 1 Jan 2023: $580K published
Quarter from 1 Apr 2023: $970K published
Quarter from 1 Oct 2023: $420K published
Quarter from 1 Jan 2024: $380K published
Quarter from 1 Apr 2024: $350K published
Quarter from 1 Jul 2024: $410K published
Quarter from 1 Oct 2024: $470K published
Quarter from 1 Jan 2025: $970K published
Quarter from 1 Apr 2025: $420K published
Quarter from 1 Oct 2025: $390K published
Quarter from 1 Jan 2026: $370K published
Quarter from 1 Apr 2026: $280K published
Quarter from 1 Jul 2026: $650K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $2.6M (5 Mar 2024), 6.2× its normal reading; higher than 78% of its own history.
Reported lobbying spend: $270K in Q3 2026, $380K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
31 Jul 2026
Ended
Mcdermott+ LLCfor Baxter International
Reimbursement, coding and coverage for inpatient and outpatient products.Medicare/Medicaid, Health issues
General issues related to providing quality kidney care services in other countries.; General issues related to home dialysis and other elements of quality kidney care, including remote patient monitoring.FOR, Health issues
Monitor funding issues related to Presidents Proposed Budget and Senate and House Appropriations, including Labor, Health and Human Services and community project funding process.; Monitor issues related to supply chain challenges, medical device and pharmaceutical industry, price transparency and drug pricing, drug shortages, CHIPS and Science Act of 2022 (P.L. No: 117-167) implementation, healthcare workforce challenges, artificial intelligence, safe mobility issues, includi; Regulatory and reimbursement policy issues relating to healthcare programs, including Medicare and Medicaid coverage and reimbursement, safe mobility issues, diabetes and diabetic retinopathy, monitor medical device, drug pricing, supply chain, innovation, and provider issues. Monitor issues regardiBudget, Health issues, Medicare/Medicaid
Issues relating to home dialysis and safe mobility; issues relating to pandemic all-hazards preparedness act; promote kidney care and positive patient outcomesHealth issues, MED
ESRD, innovation, Medicare coverage and reimbursement, new tech add-on, kidney care demonstrations, Kidney Rx, home dialysis; H.R. 5376, the Inflation Reduction Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023Medicare/Medicaid, Health issues
had 33.8M shares sold short in the 15 Jan 2026 report, 2.0× the same report last year.
Same report last year: 16.7M; its normal report is 18.7M.
See the evidence
This period
33.8M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
18.7M
Typical spread (median absolute deviation)
2.6M
How far from its usual level
+3.8
Same report last year
16.7M
History used
2,939 days
the 15 Jan 2026 report24 earlier reportsnormal: 18.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 34.2M shares sold short in the 31 Dec 2025 report, 2.7× the same report last year.
Same report last year: 12.8M; its normal report is 18.3M.
See the evidence
This period
34.2M (the 31 Dec 2025 report)
Normal report (median of 24 earlier)
18.3M
Typical spread (median absolute deviation)
2.6M
How far from its usual level
+4.0
Same report last year
12.8M
History used
2,924 days
the 31 Dec 2025 report24 earlier reportsnormal: 18.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 33.5M shares sold short in the 15 Dec 2025 report, 2.6× the same report last year.
Same report last year: 13.1M; its normal report is 18.2M.
See the evidence
This period
33.5M (the 15 Dec 2025 report)
Normal report (median of 24 earlier)
18.2M
Typical spread (median absolute deviation)
2.6M
How far from its usual level
+3.9
Same report last year
13.1M
History used
2,908 days
the 15 Dec 2025 report24 earlier reportsnormal: 18.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 33.1M shares sold short in the 28 Nov 2025 report, 2.7× the same report last year.
Same report last year: 12.4M; its normal report is 18.0M.
See the evidence
This period
33.1M (the 28 Nov 2025 report)
Normal report (median of 24 earlier)
18.0M
Typical spread (median absolute deviation)
2.6M
How far from its usual level
+3.9
Same report last year
12.4M
History used
2,891 days
the 28 Nov 2025 report24 earlier reportsnormal: 18.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 29.3M shares sold short in the 14 Nov 2025 report, 2.3× the same report last year.
Same report last year: 12.8M; its normal report is 17.6M.
See the evidence
This period
29.3M (the 14 Nov 2025 report)
Normal report (median of 24 earlier)
17.6M
Typical spread (median absolute deviation)
2.2M
How far from its usual level
+3.5
Same report last year
12.8M
History used
2,877 days
the 14 Nov 2025 report24 earlier reportsnormal: 17.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
drew 5,189 Wikipedia page views in the week of 6 Oct 2025, 1.4× the same week last year.
Same week last year: 3,705; its normal week is 1,768.
See the evidence
This period
5,189 (the week of 6 Oct 2025)
Normal week (median of 26 earlier)
1,768
Typical spread (median absolute deviation)
132
How far from its usual level
+17.1
Same week last year
3,705
History used
2,476 days
the week of 6 Oct 202526 earlier weeksnormal: 1,768
Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.
had 11.3M shares sold short in the 13 Oct 2023 report, 1.7× the same report last year.
Same report last year: 6.5M; its normal report is 6.5M.
See the evidence
This period
11.3M (the 13 Oct 2023 report)
Normal report (median of 24 earlier)
6.5M
Typical spread (median absolute deviation)
833K
How far from its usual level
+3.9
Same report last year
6.5M
History used
2,114 days
the 13 Oct 2023 report24 earlier reportsnormal: 6.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 143 entries; narrow the window or the kind of data to see older ones.
Not listed: 237 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0000010456
Ticker
BAX
Domain
baxter.com
Employer name
baxter healthcare, baxter healthcare corporation usa, Hill-Rom Services, Inc., Welch Allyn, Inc. (4 unverified)